Ophthalmology Study Notes: Retina, Optic Nerve, and Vascular/Ocular Emergencies
Retinal Detachment
Definition: Accumulation of fluid that pulls the retina away from the underlying base epithelium, or scar tissue causes traction detachment. The retina detaches from the back wall of the eye.
Presentation: Acute and sudden. Occurs in minutes (e.g., 10–20 minutes). Not gradual over days.
Symptoms: Flashes, floaters, and painless loss of vision with a curtain or veil over part of the vision. Vision loss can start peripherally and progress; visual acuity may be preserved early on.
Visual description: A piece of retina floats away, causing a curtain-like loss of vision. Some acuity may remain despite detachment.
Diagnosis clues: If patient reports curtain-like loss, ask targeted questions because many won’t describe it explicitly.
Exam/Imaging: Primary care may do a dilated fundoscopic exam to evaluate the back of the retina. Ocular ultrasound can help if view is limited. CT/MRI mainly for trauma; fundoscopy can reveal detachment.
Variants seen with complications: Retinal detachment with hemorrhage can occur when a detached retina tears a blood vessel; this increases risk of permanent vision loss due to hemorrhage and scar tissue.
Treatment/Management:
Immediate referral to an ophthalmologist (same-day, not next day). If no ophthalmologist in practice, send to ED for on-call ophthalmologist.
Laser photocoagulation or cryotherapy to seal the retina to the back of the wall.
Pneumatic retinopexy: gas bubble injection into the vitreous to push the retina back into place.
Scleral buckle with vitrectomy: surgical approach that brings the back of the eye closer to the detached area (less commonly used nowadays due to discomfort).
Key takeaway: This is an ocular emergency requiring rapid intervention to reattach retina and prevent irreversible vision loss.
Retinal Vascular Occlusions (Retinal Vascular Events)
Concept: A retinal vascular occlusion is like a stroke in the eye, caused by a clot or occlusion reducing blood flow. Can be transient or permanent.
Amaurosis fugax (amaurosis fugax boojacks): transient monocular vision loss due to arterial insufficiency; Greek roots: amauros = dark, phobos/fujax related to bleeding; important board concept.
Types (arteries and veins): CRAs and BRAs (arteries) vs CRVs and BRVs (veins).
General risk factors: aging, hypertension, diabetes, smoking, obesity, hypercoagulable states, glaucoma increasing risk of occlusions.
Diagnostics: history and physical, fluorescein angiography, carotid Doppler ultrasound, echocardiography, and basic labs (lipids, CBC, CMP) to evaluate risk factors.
Central Retinal Artery Occlusion (CRAO)
Definition: Occlusion of the central retinal artery feeding the eye; true ocular emergency with poor prognosis for visual recovery.
Time sensitivity: Restoration of blood flow within can prevent retinal injury; occlusions persisting for cause irreversible damage.
Etiology: Atherosclerotic emboli from carotids or heart; arterial emboli cause CRAO.
Fundoscopy: Pale retina with a cherry red spot at the fovea.
Management in the ER: Thrombolytics (clot-busting therapy), reduction of intraocular pressure, and digital ocular massage to try to restore flow; urgent ophthalmology consultation.
Branch Retinal Artery Occlusion (BRAO)
Definition: Occlusion of a branch of the central retinal artery; partial, painless loss of vision corresponding to affected area.
Management: Similar immediate steps as CRAO (emergency referral, possible thrombolysis, ocular massage).
Central Retinal Vein Occlusion (CRVO)
Definition: Vein occlusion; second most common cause of visual loss from retinal vascular disease in the elderly.
Presentation: Painless, gradual or subacute onset (hours to weeks).
Exam/findings: Blood and thunder appearance with engorged veins, cotton-wool spots, retinal hemorrhages, and optic disc swelling.
Management: Refer to ophthalmology; not always emergent to ER; address underlying cardiovascular risks; laser treatment may be used to treat secondary neovascularization.
Branch Retinal Vein Occlusion (BRVO)
Definition: Vein occlusion of a branch, not the entire retina.
Presentation: Painless, gradual or subacute; limited to one quadrant.
Exam/findings: Retinal hemorrhages, cotton-wool spots, dilated venules in the affected quadrant.
Management: Similar to CRVO; address underlying cardiovascular conditions; monitor with ophthalmology; laser may treat secondary neovascularization.
Practical distinctions
Central events (CRAO/CRVO) are more emergent than branch events; CRAO is an ocular emergency with time-sensitive intervention; BRVO/CRVO require prompt specialist follow-up but are not always ER emergencies.
Optic Neuropathy (Damage to the Optic Nerve)
General concept: Damage to the optic nerve can be acute or chronic and typically presents with monocular vision loss.
Key clinical features across optic neuropathies:
Usually unilateral; bilateral involvement is less common
Eye pain with movement (especially optic neuritis) is a distinguishing feature
Loss of color vision
Relative Afferent Pupillary Defect (RAPD; Marcus Gunn pupil): affected eye’s pupil dilates when light is swung to it due to diminished afferent input; most sensitive objective sign of unilateral optic nerve lesion or asymmetric bilateral lesions
RAPD test history: historically described in colorful terms; modern teaching emphasizes its diagnostic value for unilateral optic nerve disease
Optic Neuritis
Pathophysiology: Inflammatory demyelinating process of the optic nerve; often associated with multiple sclerosis (MS)
Presentation: Acute or subacute vision loss in one eye; eye pain with movement; decreased color vision; RAPD; may be associated with MS
Diagnosis: Brain and orbit MRI to evaluate for MS or optic nerve pathology; look for demyelinating lesions
Treatment: IV methylprednisolone (steroids) often administered by neurology/ophthalmology; prompt treatment improves prognosis
Prognosis: Generally good visual recovery with treatment, though MS risk monitoring required
Ischemic Optic Neuropathy
Nonarteritic (NAION)
Most common form
Etiology: Noninflammatory reduction of blood flow to the optic nerve; risk factors include hypertension, diabetes, older age
Presentation: Sudden, painless vision loss in one eye; may have altitudinal defects; RAPD
Distinguishing features: No inflammatory signs; often associated with vascular risk factors
Arteritic (AAION) – Giant Cell (Temporal) Arteritis related
Etiology: Inflammatory reduction of blood flow due to vasculitis (giant cell arteritis)
Presentation: Sudden unilateral vision loss; may have headache, malaise, jaw claudication, fever; temporal artery tenderness; possible diplopia
Diagnosis: ESR/CRP elevated; temporal artery biopsy gold standard, but color duplex ultrasound halo sign can aid diagnosis; treatment is urgent
Treatment: IV corticosteroids promptly with urgent involvement of neurology and ophthalmology to prevent bilateral involvement
Summary points on optic neuropathies
RAPD is a key sign; differential includes optic neuritis (often MS-related) vs ischemic etiologies (NAION/AAION)
MS association with optic neuritis is a critical link to consider
Giant Cell Arteritis is a true ocular emergency due to risk of bilateral blindness and systemic disease; treat empirically with steroids while confirming diagnosis
Giant Cell Arteritis (Temporal Arteritis)
Definition: True inflammatory systemic vasculitis affecting medium-to-large arteries, including the temporal artery
Demographics: More common in older adults; higher in females
Classic symptoms: Headache, temporal/scalp tenderness, jaw claudication, malaise; flu-like systemic symptoms; transient monocular vision loss (amaurosis fugax) may precede permanent loss; diplopia can occur
Diagnosis: Blood tests (ESR/CRP); temporal artery biopsy is the gold standard but color duplex ultrasound showing a halo sign is commonly used; a biopsy may be deferred in urgent cases if imaging supports diagnosis
Management: Immediate initiation of IV corticosteroids with urgent specialty involvement (ophthalmology and neurology); goals are to prevent contralateral eye involvement and systemic complications
Prognosis: Vision preservation depends on prompt treatment; early recognition is critical to prevent irreversible visual loss and systemic complications
Age-Related Macular Degeneration (AMD)
Definition: Degeneration of the macula, the central portion of the retina responsible for central vision
Epidemiology: Most common cause of severe vision loss in elderly in developed countries; risk increases with age
Risk factors: Age, female gender (higher risk), smoking, family history, cardiovascular disease, hypertension, high cholesterol, obesity
Symptoms and signs:
Early AMD may be asymptomatic; central vision gradually worsens
Distortion of straight lines: lines appear wavy (metamorphopsia)
Scotomas and decreased central vision; difficulty discerning details
Drusen presence in the macula is a hallmark of AMD; drusen elsewhere may be normal aging
Visual distortions may precede noticeable vision loss
Types:
Dry AMD (non-neovascular): Most common (≈85–90% of cases)
Pathophysiology: Complement-system–mediated inflammatory degeneration and retinal cell death; geographic atrophy may occur
Fundoscopy: Drusen and geographic atrophy in the macula
Wet AMD (neovascular): Less common but responsible for most severe vision loss
Pathophysiology: Growth of fragile new vessels under the retina (neovascularization) leading to leakage and hemorrhage
Fundoscopy: Drusen with neovascularization and hemorrhages; potential for rapid vision loss
Diagnosis/Monitoring:
Amsler grid testing to detect distortion; grid is used at home and in clinic
Fundoscopic exam and imaging (emerging standard includes OCT and fluorescein angiography)
Objective monitoring with regular follow-up (every 6–12 months) by an ophthalmologist
Management:
Dry AMD:
Antioxidant supplementation historically studied (AREDS/AREDS2 findings suggested vitamins C, E, and zinc may slow progression)
Complement inhibitors are a newer therapeutic approach targeting inflammatory pathways involved in dry AMD progression
Lifestyle: avoid smoking, UV protection, nutrition optimization
Regular monitoring by retina specialist
Wet AMD:
Primary treatment is VEGF inhibitors delivered by intravitreal injection to inhibit neovascularization (e.g., ranibizumab, aflibercept, bevacizumab); reduces fluid and hemorrhage and stabilizes vision
Maintain regular injections as directed; response varies
General: avoid smoking, maintain good cardiovascular health, and protect eyes from UV exposure; routine monitoring with Amsler grid and retina specialist follow-up
Diabetic Retinopathy
Definition: Retinal changes in patients with diabetes, affecting the microvasculature of the retina
Epidemiology: Number one cause of blindness in the US for working-age adults; risk increases with duration of diabetes and poor glycemic control
Stages:
Nonproliferative retinopathy: microaneurysms, hemorrhages, hard exudates, cotton-wool spots; vision may be preserved initially
Proliferative retinopathy: neovascularization, fibrovascular tissue, vitreous hemorrhage, tractional retinal detachment; high risk of vision loss
Presentation: Floaters, blurry vision, color vision changes; symptoms depend on stage and severity
Management: Emphasize systemic control (blood glucose, blood pressure); laser photocoagulation to prevent neovascularization and vision loss; anti-VEGF therapies may be used in proliferative disease (not explicitly stated in the transcript, but commonly used in practice)
Monitoring: Regular ophthalmologic exams to detect progression and implement timely treatment
Hypertensive Retinopathy
Chronic hypertension effects: Affects both retinal and choroidal circulation; accelerates atherosclerosis in retinal vessels
Classic findings in chronic hypertension:
Tortuous retinal arterioles
Copper wiring or silver wiring (altered light reflex)
AV nicking (arteriolar thickening causes compression of venules)
Flame-shaped retinal hemorrhages
Acute malignant hypertension (medical emergency):
Definition: Diastolic blood pressure > (diastolic BP > 120)
Ocular findings: papilledema (optic disc swelling), retinal hemorrhages, cotton-wool spots, and potentially edema
Risks: 2–4 fold increased risk of stroke if signs are present
Management: Immediate hospital admission with IV blood pressure management; urgent evaluation and treatment
Protective measures for all hypertensive patients: yearly comprehensive eye exams to monitor for hypertensive retinopathy and other ocular complications
Practice Questions and Case Scenarios
Case 1: 60-year-old male with sudden, painless loss of vision in the right eye, onset within 6 hours, top-half vision affected, floaters and flashes present
Differential: Retinal detachment is most likely ( curtain-like loss ), ocular emergency
Answer: Retinal detachment; requires urgent ophthalmology referral
Case 2: Which retinal vascular occlusion is a medical emergency?
Options: CRAO, BRAO, CRVO, BRVO
Answer: Central Retinal Artery Occlusion (CRAO) – true ocular emergency; immediate evaluation and therapy needed
Case 3: 45-year-old female with two weeks of decreasing vision in the left eye, painless, gradual, color vision loss; history of chronic migraines; MRI planned by neurologist for weakness in legs
Top differential: Optic neuritis (likely MS-associated)
Associated condition: Multiple sclerosis
Treatment: IV methylprednisolone; urgent referral to neurology/ophthalmology; MRI brain/orbits to assess for MS
Case 4: Classic AMD symptom and test
Hallmark symptom: Straight lines appear wavy (metamorphopsia)
Best diagnostic test: Amsler grid (Ansler grid) to detect distortion
Drusen sign in macula differentiates AMD from normal aging
Case 5: Fundoscopic hallmark of AMD in wet vs dry
Dry AMD: Drusen with geographic atrophy; slower progression
Wet AMD: Drusen with neovascularization and hemorrhages; emphasizes VEGF-driven treatment
Case 6: Management of giant cell arteritis (temporal arteritis)
Urgent signs: unilateral vision loss with systemic symptoms; temporal artery tenderness; jaw claudication
Diagnostic approach: ESR/CRP; temporal artery biopsy (gold standard) or color duplex ultrasound halo sign
Treatment: IV corticosteroids and urgent multidisciplinary involvement to prevent contralateral involvement and systemic complications
Retinal Detachment
Definition: Accumulation of fluid that pulls the retina away from the underlying base epithelium, or scar tissue causes traction detachment. The retina detaches from the back wall of the eye.
Presentation: Acute and sudden. Occurs in minutes (e.g., 10–20 minutes). Not gradual over days.
Symptoms: Flashes, floaters, and painless loss of vision with a curtain or veil over part of the vision. Vision loss can start peripherally and progress; visual acuity may be preserved early on.
Visual description: A piece of retina floats away, causing a curtain-like loss of vision. Some acuity may remain despite detachment.
Diagnosis clues: If patient reports curtain-like loss, ask targeted questions because many won’t describe it explicitly.
Exam/Imaging: Primary care may do a dilated fundoscopic exam to evaluate the back of the retina. Ocular ultrasound can help if view is limited. CT/MRI mainly for trauma; fundoscopy can reveal detachment.
Variants seen with complications: Retinal detachment with hemorrhage can occur when a detached retina tears a blood vessel; this increases risk of permanent vision loss due to hemorrhage and scar tissue.
Treatment/Management:- Immediate referral to an ophthalmologist (same-day, not next day). If no ophthalmologist in practice, send to ED for on-call ophthalmologist.
Laser photocoagulation or cryotherapy to seal the retina to the back of the wall.
Pneumatic retinopexy: gas bubble injection into the vitreous to push the retina back into place.
Scleral buckle with vitrectomy: surgical approach that brings the back of the eye closer to the detached area (less commonly used nowadays due to discomfort).
Key takeaway: This is an ocular emergency requiring rapid intervention to reattach retina and prevent irreversible vision loss.
Retinal Vascular Occlusions (Retinal Vascular Events)
Concept: A retinal vascular occlusion is like a stroke in the eye, caused by a clot or occlusion reducing blood flow. Can be transient or permanent.
Amaurosis fugax (amaurosis fugax boojacks): transient monocular vision loss due to arterial insufficiency; Greek roots: amauros = dark, phobos/fujax related to bleeding; important board concept.
Types (arteries and veins): CRAs and BRAs (arteries) vs CRVs and BRVs (veins).
General risk factors: aging, hypertension, diabetes, smoking, obesity, hypercoagulable states, glaucoma increasing risk of occlusions.
Diagnostics: history and physical, fluorescein angiography, carotid Doppler ultrasound, echocardiography, and basic labs (lipids, CBC, CMP) to evaluate risk factors.
Central Retinal Artery Occlusion (CRAO)- Definition: Occlusion of the central retinal artery feeding the eye; true ocular emergency with poor prognosis for visual recovery.
Time sensitivity: Restoration of blood flow within can prevent retinal injury; occlusions persisting for cause irreversible damage.
Etiology: Atherosclerotic emboli from carotids or heart; arterial emboli cause CRAO.
Fundoscopy: Pale retina with a cherry red spot at the fovea.
Management in the ER: Thrombolytics (clot-busting therapy), reduction of intraocular pressure, and digital ocular massage to try to restore flow; urgent ophthalmology consultation.
Branch Retinal Artery Occlusion (BRAO)- Definition: Occlusion of a branch of the central retinal artery; partial, painless loss of vision corresponding to affected area.
Management: Similar immediate steps as CRAO (emergency referral, possible thrombolysis, ocular massage).
Central Retinal Vein Occlusion (CRVO)- Definition: Vein occlusion; second most common cause of visual loss from retinal vascular disease in the elderly.
Presentation: Painless, gradual or subacute onset (hours to weeks).
Exam/findings: Blood and thunder appearance with engorged veins, cotton-wool spots, retinal hemorrhages, and optic disc swelling.
Management: Refer to ophthalmology; not always emergent to ER; address underlying cardiovascular risks; laser treatment may be used to treat secondary neovascularization.
Branch Retinal Vein Occlusion (BRVO)- Definition: Vein occlusion of a branch, not the entire retina.
Presentation: Painless, gradual or subacute; limited to one quadrant.
Exam/findings: Retinal hemorrhages, cotton-wool spots, dilated venules in the affected quadrant.
Management: Similar to CRVO; address underlying cardiovascular conditions; monitor with ophthalmology; laser may treat secondary neovascularization.
Practical distinctions- Central events (CRAO/CRVO) are more emergent than branch events; CRAO is an ocular emergency with time-sensitive intervention; BRVO/CRVO require prompt specialist follow-up but are not always ER emergencies.
Optic Neuropathy (Damage to the Optic Nerve)
General concept: Damage to the optic nerve can be acute or chronic and typically presents with monocular vision loss.
Key clinical features across optic neuropathies:- Usually unilateral; bilateral involvement is less common
Eye pain with movement (especially optic neuritis) is a distinguishing feature
Loss of color vision
Relative Afferent Pupillary Defect (RAPD; Marcus Gunn pupil): affected eye’s pupil dilates when light is swung to it due to diminished afferent input; most sensitive objective sign of unilateral optic nerve lesion or asymmetric bilateral lesions
RAPD test history: historically described in colorful terms; modern teaching emphasizes its diagnostic value for unilateral optic nerve disease
Optic Neuritis- Pathophysiology: Inflammatory demyelinating process of the optic nerve; often associated with multiple sclerosis (MS)
Presentation: Acute or subacute vision loss in one eye; eye pain with movement; decreased color vision; RAPD; may be associated with MS
Diagnosis: Brain and orbit MRI to evaluate for MS or optic nerve pathology; look for demyelinating lesions
Treatment: IV methylprednisolone (steroids) often administered by neurology/ophthalmology; prompt treatment improves prognosis
Prognosis: Generally good visual recovery with treatment, though MS risk monitoring required
Ischemic Optic Neuropathy- Nonarteritic (NAION)
Most common form
Etiology: Noninflammatory reduction of blood flow to the optic nerve; risk factors include hypertension, diabetes, older age
Presentation: Sudden, painless vision loss in one eye; may have altitudinal defects; RAPD
Distinguishing features: No inflammatory signs; often associated with vascular risk factors
Arteritic (AAION) – Giant Cell (Temporal) Arteritis related
Etiology: Inflammatory reduction of blood flow due to vasculitis (giant cell arteritis)
Presentation: Sudden unilateral vision loss; may have headache, malaise, jaw claudication, fever; temporal artery tenderness; possible diplopia
Diagnosis: ESR/CRP elevated; temporal artery biopsy gold standard, but color duplex ultrasound halo sign can aid diagnosis; treatment is urgent
Treatment: IV corticosteroids promptly with urgent involvement of neurology and ophthalmology to prevent bilateral involvement
Summary points on optic neuropathies- RAPD is a key sign; differential includes optic neuritis (often MS-related) vs ischemic etiologies (NAION/AAION)
MS association with optic neuritis is a critical link to consider
Giant Cell Arteritis is a true ocular emergency due to risk of bilateral blindness and systemic disease; treat empirically with steroids while confirming diagnosis
Giant Cell Arteritis (Temporal Arteritis)
Definition: True inflammatory systemic vasculitis affecting medium-to-large arteries, including the temporal artery
Demographics: More common in older adults; higher in females
Classic symptoms: Headache, temporal/scalp tenderness, jaw claudication, malaise; flu-like systemic symptoms; transient monocular vision loss (amaurosis fugax) may precede permanent loss; diplopia can occur
Diagnosis: Blood tests (ESR/CRP); temporal artery biopsy is the gold standard but color duplex ultrasound showing a halo sign is commonly used; a biopsy may be deferred in urgent cases if imaging supports diagnosis
Management: Immediate initiation of IV corticosteroids with urgent specialty involvement (ophthalmology and neurology); goals are to prevent contralateral eye involvement and systemic complications
Prognosis: Vision preservation depends on prompt treatment; early recognition is critical to prevent irreversible visual loss and systemic complications
Age-Related Macular Degeneration (AMD)
Definition: Degeneration of the macula, the central portion of the retina responsible for central vision
Epidemiology: Most common cause of severe vision loss in elderly in developed countries; risk increases with age
Risk factors: Age, female gender (higher risk), smoking, family history, cardiovascular disease, hypertension, high cholesterol, obesity
Symptoms and signs:- Early AMD may be asymptomatic; central vision gradually worsens
Distortion of straight lines: lines appear wavy (metamorphopsia)
Scotomas and decreased central vision; difficulty discerning details
Drusen presence in the macula is a hallmark of AMD; drusen elsewhere may be normal aging
Visual distortions may precede noticeable vision loss
Types:- Dry AMD (non-neovascular): Most common ( of cases)
Pathophysiology: Complement-system–mediated inflammatory degeneration and retinal cell death; geographic atrophy may occur
Fundoscopy: Drusen and geographic atrophy in the macula
Wet AMD (neovascular): Less common but responsible for most severe vision loss
Pathophysiology: Growth of fragile new vessels under the retina (neovascularization) leading to leakage and hemorrhage
Fundoscopy: Drusen with neovascularization and hemorrhages; potential for rapid vision loss
Diagnosis/Monitoring:- Amsler grid testing to detect distortion; grid is used at home and in clinic
Fundoscopic exam and imaging (emerging standard includes OCT and fluorescein angiography)
Objective monitoring with regular follow-up (every ) by an ophthalmologist
Management:- Dry AMD:
Antioxidant supplementation historically studied (AREDS/AREDS2 findings suggested vitamins C, E, and zinc may slow progression)
Complement inhibitors are a newer therapeutic approach targeting inflammatory pathways involved in dry AMD progression
Lifestyle: avoid smoking, UV protection, nutrition optimization
Regular monitoring by retina specialist
Wet AMD:
Primary treatment is VEGF inhibitors delivered by intravitreal injection to inhibit neovascularization (e.g., ranibizumab, aflibercept, bevacizumab); reduces fluid and hemorrhage and stabilizes vision
Maintain regular injections as directed; response varies
General: avoid smoking, maintain good cardiovascular health, and protect eyes from UV exposure; routine monitoring with Amsler grid and retina specialist follow-up
Diabetic Retinopathy
Definition: Retinal changes in patients with diabetes, affecting the microvasculature of the retina
Epidemiology: Number one cause of blindness in the US for working-age adults; risk increases with duration of diabetes and poor glycemic control
Stages:- Nonproliferative retinopathy: microaneurysms, hemorrhages, hard exudates, cotton-wool spots; vision may be preserved initially
Proliferative retinopathy: neovascularization, fibrovascular tissue, vitreous hemorrhage, tractional retinal detachment; high risk of vision loss
Presentation: Floaters, blurry vision, color vision changes; symptoms depend on stage and severity
Management: Emphasize systemic control (blood glucose, blood pressure); laser photocoagulation to prevent neovascularization and vision loss; anti-VEGF therapies may be used in proliferative disease (not explicitly stated in the transcript, but commonly used in practice)
Monitoring: Regular ophthalmologic exams to detect progression and implement timely treatment
Hypertensive Retinopathy
Chronic hypertension effects: Affects both retinal and choroidal circulation; accelerates atherosclerosis in retinal vessels
Classic findings in chronic hypertension:- Tortuous retinal arterioles
Copper wiring or silver wiring (altered light reflex)
AV nicking (arteriolar thickening causes compression of venules)
Flame-shaped retinal hemorrhages
Acute malignant hypertension (medical emergency):- Definition: Diastolic blood pressure > (diastolic BP > 120)
Ocular findings: papilledema (optic disc swelling), retinal hemorrhages, cotton-wool spots, and potentially edema
Risks: fold increased risk of stroke if signs are present
Management: Immediate hospital admission with IV blood pressure management; urgent evaluation and treatment
Protective measures for all hypertensive patients: yearly comprehensive eye exams to monitor for hypertensive retinopathy and other ocular complications
Practice Questions and Case Scenarios (Likely Exam Material)
These scenarios represent key concepts and common presentations that may be tested:
Case 1: Retinal Detachment is most likely
Presentation: 60-year-old male with sudden, painless loss of vision in the right eye, onset within , top-half vision affected, floaters and flashes present.
Key Features: Sudden, painless, floaters, flashes, curtain-like vision loss (implied).
Action: Urgent ophthalmology referral (ocular emergency).
Case 2: Central Retinal Artery Occlusion (CRAO) is a medical emergency
Question: Which retinal vascular occlusion is a medical emergency?
Key Concept: CRAO is a true ocular emergency requiring immediate evaluation and therapy.
Case 3: Optic Neuritis (likely MS-associated)
Presentation: 45-year-old female with two weeks of decreasing vision in the left eye, painless, gradual, color vision loss; history of chronic migraines; MRI planned by neurologist for weakness in legs.
Key Features: Gradual vision loss, color vision loss, eye pain with movement (often present), RAPD (implied), associated with MS.
Action: IV methylprednisolone; urgent referral to neurology/ophthalmology; MRI brain/orbits to assess for MS.
Case 4: Classic AMD symptom and diagnostic test
Hallmark Symptom: Straight lines appear wavy (metamorphopsia).
Best Diagnostic Test: Amsler grid to detect distortion.
Key Sign: Drusen in the macula differentiates AMD from normal aging.
Case 5: Fundoscopic hallmark of AMD (Wet vs Dry)
Dry AMD: Drusen with geographic atrophy; slower progression.
Wet AMD: Drusen with neovascularization and hemorrhages; emphasizes VEGF-driven treatment.
Case 6: Management of Giant Cell Arteritis (Temporal Arteritis)
Urgent Signs: Unilateral vision loss with systemic symptoms (headache, malaise, jaw claudication, flu-like symptoms), temporal artery tenderness.
Diagnostic Approach: ESR/CRP; temporal artery biopsy (gold standard) or color duplex ultrasound halo sign.
Treatment: Immediate initiation of IV corticosteroids and urgent multidisciplinary involvement to prevent contralateral involvement and systemic complications.